Navigation Links
AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Date:11/17/2010

ALISO VIEJO, Calif., Nov. 17, 2010 /PRNewswire-FirstCall/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock, offered at a price of $4.40 per share.  The offering is expected to close on or about November 22, 2010, subject to customary closing conditions.  In addition, AVANIR has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock to cover over-allotments, if any.  Jefferies & Company, Inc. is acting as sole book-running manager in the offering and Canaccord Genuity Inc., Wedbush PacGrow Life Sciences, Summer Street Research Partners, and Merriman Capital are acting as co-managers for the offering.  In addition Trout Capital LLC is serving as a financial advisor to AVANIR.

Gross offering proceeds will be approximately $88,000,000, before deducting customary underwriting discounts and commissions and offering expenses. AVANIR intends to use the net proceeds from this offering for sales and marketing activities relating to its newly approved product NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate).  In addition, the proceeds may be used for further clinical, regulatory and commercial development of NUEDEXTA, as well as potential business development activities and for general working capital.

Registration statements relating to the shares of common stock issued in the offering have been filed with, and declared effective by, the Securities and Exchange Commission (the "SEC").  A final prospectus supplement relating to the offering will be filed with the SEC.  Copies of the final prospectus supplement and related prospectuses, when available, may be obtained from Equity Syndicate Prospectus Department, Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY, 10022, at (877) 547-6340, and at Prospectus_Department@Jefferies.com.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Forward Looking Statements

Statements in this press release that are not historical facts, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, may be forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from the future results expressed or implied by such statements. These statements include, but are not limited to, AVANIR's ability to successfully market and sell NUEDEXTA in the United States, the safety and efficacy of NUEDEXTA, and the anticipated timing and success of the commercial launch of NUEDEXTA. Risks that could cause actual results to differ include the occurrence of adverse safety events with NUEDEXTA, our limited capital resources, our dependence on third parties for manufacturing and distribution of NUEDEXTA, that we may not adequately build or maintain the necessary sales, marketing, supply chain management and reimbursement capabilities on our own or enter into arrangements with third parties to perform these functions in a timely manner or on acceptable terms, and other risks that are described in further detail in the offering prospectus and in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and from time-to time in other publicly available information regarding the Company. Copies of this information are available from us upon request. We disclaim any intent to update these forward-looking statements.


'/>"/>
SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
2. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
3. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
4. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
5. Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
6. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
7. Vanda Pharmaceuticals Appoints Chief Financial Officer
8. Jazz Pharmaceuticals Announces Presentation at the Lazard Capital Markets Healthcare Conference on November 17
9. Transcept Pharmaceuticals Reports Third Quarter 2010 Financial Results
10. Cumberland Pharmaceuticals Reports Third Quarter 2010 Financial Results
11. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017   Pulmatrix, Inc . (NASDAQ: PULM), a ... serious pulmonary diseases, today announced that it has added two ... and asthma to its Scientific Advisory Board . ... Richard B. Moss , MD, former chief of the Pediatric ... Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... , March 27, 2017 ... to reach USD 16.0 billion by 2025, according to ... growing prevalence of chronic diseases is anticipated to be ... analyzers, which thereby widens the scope for growth during ... and bariatric population, which is highly susceptible to chronic ...
(Date:3/27/2017)... BOSTON , March 27, 2017  Allergan ... and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical ... innovative therapies based upon tetracycline chemistry, announced that ... the treatment of moderate to severe acne met ... a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with ...
Breaking Medicine Technology:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... announces today that the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® ... Western Pennsylvania. , The program, developed in association with efforts by the American ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
(Date:3/28/2017)... ... 2017 , ... In its ongoing effort to educate consumers ... and published an informational resource that addresses frequently asked questions. , “ ... site’s team of third party administrator (TPA) contributors regularly receives as employers, benefit ...
(Date:3/28/2017)... Santa Monica, CA (PRWEB) , ... March 28, ... ... expert, Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer ... newest gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s ...
(Date:3/28/2017)... ... ... a common and unwelcomed occurrence in people of all ages, genders and ethnicities. Dermatologist Dr. ... of dealing with excess skin oil. “Oily skin is a challenge to many of my ... the oily shine while keeping the skin fresh and clean,” says Dr. Au. , What ...
Breaking Medicine News(10 mins):